TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.800
+0.250 (5.49%)
At close: Feb 11, 2026, 4:00 PM EST
4.800
0.00 (0.00%)
After-hours: Feb 11, 2026, 4:32 PM EST
TriSalus Life Sciences Revenue
TriSalus Life Sciences had revenue of $11.57M in the quarter ending September 30, 2025, with 57.38% growth. This brings the company's revenue in the last twelve months to $40.21M, up 49.52% year-over-year. In the year 2024, TriSalus Life Sciences had annual revenue of $29.43M with 58.99% growth.
Revenue (ttm)
$40.21M
Revenue Growth
+49.52%
P/S Ratio
3.94
Revenue / Employee
$365,518
Employees
110
Market Cap
239.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.43M | 10.92M | 58.99% |
| Dec 31, 2023 | 18.51M | 6.11M | 49.31% |
| Dec 31, 2022 | 12.40M | 4.00M | 47.58% |
| Dec 31, 2021 | 8.40M | 2.97M | 54.60% |
| Dec 31, 2020 | 5.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Quanterix | 130.20M |
| Sight Sciences | 76.05M |
| Electromed | 66.22M |
| 908 Devices | 65.05M |
| CVRx, Inc. | 55.97M |
| Apyx Medical | 47.90M |
| SANUWAVE Health | 41.28M |
| Rapid Micro Biosystems | 30.52M |
TLSI News
- 2 days ago - TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors - Business Wire
- 4 weeks ago - TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance - Business Wire
- 2 months ago - TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript - Seeking Alpha
- 2 months ago - TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 - Business Wire
- 3 months ago - TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™ - Business Wire
- 3 months ago - TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance - Business Wire
- 3 months ago - TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript - Seeking Alpha